LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer

Video

“There’s a lot of clinical utility to genetic testing, and there are familial implications and clinical trial implications,” explains Neal Shore, MD.

Neal Shore, MD, explains how genetic testing has become an essential component of the treatment paradigm for patients with prostate cancer. Shore is co-chairing the CME program at the 2022 LUGPA Annual Meeting, which will include a session on genetic testing. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).

Related Videos
Bradley Gill, MD, MS, answers a question during a Zoom video interview
Katie S. Murray, DO, answers a question during a Zoom video interview
Kelly L. Stratton, MD, FACS, answers a question during a Zoom video interview
R. Jonathan Henderson, MD, in an interview with Urology Times
Urologist J. Christopher Webster, MD, FACS, answers a question during an interview
Benjamin Lowentritt, MD, FACS, in an interview with Urology Times
R. Jonathan Henderson in an interview at the LUGPA Annual Conference
Joshua J. Meeks, MD, PhD, in an interview at the 2022 Annual LUGPA Meeting
Related Content
© 2023 MJH Life Sciences

All rights reserved.